Equifax (NYSE: EFX) CEO logs major option exercise and 10b5-1 stock sales
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Equifax Inc. CEO and director Mark W. Begor reported multiple equity transactions dated 02/10/2026. He exercised a stock option for 37,791 shares of common stock at an exercise price of $112.46 per share and received a separate grant of 33,278 common shares at $0.0000.
On the same day, he executed a series of open-market sales of common stock at weighted average prices ranging from $192.8855 to $203.0792 per share, including blocks such as 11,000 and 18,352 shares. A further 1,759 shares were withheld at $202.71 to cover tax obligations.
After these transactions, Begor directly held 230,506 common shares and maintained additional indirect holdings through several GRAT vehicles, including 10,500, 21,284, 22,045, 12,333, and 16,287 shares. The sales were carried out under a Rule 10b5-1 trading plan adopted on 10/28/2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 37,791 shares ($7,629,521)
Net Sell
20 txns
Insider
Begor Mark W
Role
CEO
Sold
37,791 shs ($7.63M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option/Right to Buy | 37,791 | $0.00 | -- |
| Exercise | Common Stock | 37,791 | $112.46 | $4.25M |
| Grant/Award | Common Stock | 33,278 | $0.00 | -- |
| Sale | Common Stock | 201 | $197.7889 | $40K |
| Sale | Common Stock | 213 | $203.7607 | $43K |
| Sale | Common Stock | 227 | $192.8855 | $44K |
| Sale | Common Stock | 331 | $194.221 | $64K |
| Sale | Common Stock | 364 | $195.3979 | $71K |
| Sale | Common Stock | 445 | $196.428 | $87K |
| Sale | Common Stock | 829 | $199.001 | $165K |
| Tax Withholding | Common Stock | 1,759 | $202.71 | $357K |
| Sale | Common Stock | 1,772 | $200.0293 | $354K |
| Sale | Common Stock | 4,057 | $201.2626 | $817K |
| Sale | Common Stock | 11,000 | $203.0792 | $2.23M |
| Sale | Common Stock | 18,352 | $202.1545 | $3.71M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option/Right to Buy — 113,374 shares (Direct);
Common Stock — 236,778 shares (Direct);
Common Stock — 10,500 shares (Indirect, 2-yr 2025 GRAT)
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $197.524 to $198.008, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $203.675 to $203.85, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $192.556 to $193.366, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $193.735 to $194.661, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $194.892 to $195.779, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $196.123 to $196.912, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $198.645 to $199.62, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $199.67 to $200.481, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $200.672 to $201.66, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $202.665 to $203.64, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $201.67 to $202.66, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. The option vested in three equal annual increments beginning 5/4/2019.
FAQ
What did Equifax (EFX) CEO Mark W. Begor report on this Form 4?
Mark W. Begor reported exercising stock options, receiving a stock grant, and selling Equifax common shares. The filing details option exercise, new share awards, open-market sales, tax-withholding share dispositions, and his resulting direct and indirect ownership positions in Equifax stock.
What does the tax-withholding transaction in the Equifax (EFX) Form 4 represent?
The Form 4 shows a code F transaction where 1,759 Equifax shares were disposed of at $202.71 per share. This reflects shares withheld to satisfy tax obligations related to equity awards, rather than an open-market sale initiated for portfolio purposes.
What is the Rule 10b5-1 trading plan noted in the Equifax (EFX) CEO’s filing?
The filing states that the reported sales were effected under a Rule 10b5-1 trading plan adopted on 10/28/2025. Such plans pre-schedule trades, allowing insiders to systematically sell shares according to predetermined instructions, helping separate trading decisions from later market-sensitive information.
What are the CEO’s indirect Equifax (EFX) holdings through GRATs?
In addition to direct holdings, Begor reports indirect ownership of Equifax shares through several grantor retained annuity trusts. These include positions of 10,500, 21,284, 22,045, 12,333, and 16,287 shares in distinct 2-year and 3-year GRAT structures identified by their respective start dates.
How many Equifax (EFX) options does the CEO hold after the reported exercise?
After exercising 37,791 stock options at $112.46, the Form 4 shows 113,374 derivative securities beneficially owned. These remaining stock options relate to Equifax common stock, with an expiration date of 05/04/2028 and prior vesting beginning on 05/04/2019.